Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Worel, N; Rosskopf, K; Neumeister, P; Kasparu, H; Nachbaur, D; Russ, G; Namberger, K; Witt, V; Schloegl, E; Zojer, N; Linkesch, W; Kalhs, P; Greinix, HT.
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Transfusion. 2011; 51(5):968-975
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Greinix Hildegard
Linkesch Werner
Neumeister Peter
Rosskopf Konrad
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) has been shown to enhance stem cell mobilization in patients with multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's disease who demonstrated with previous mobilization failure. In this named patient program we report the Austrian experience in insufficiently mobilizing patients. Twenty-seven patients from eight Austrian centers with a median (range) age of 58 (19-70) years (18 female, nine male) were included in the study. Plerixafor was limited to patients with previous stem cell mobilization failure and was given in the evening of Day 4 of G-CSF application. A median increase of circulating CD34+ cells within 10 to 11 hours from administration of plerixafor by a factor of 4.7 over baseline was noted. Overall, 20 (74%) patients reached more than 10 × 10(6) CD34+ cells/L in the peripheral blood, resulting in 17 (63%) patients collecting at least 2 × 10(6) CD34+ cells/kg body weight (b.w.; median, 2.6 × 10(6) CD34+ cells/kg b.w.; range, 0.08 × 10(6) -8.07 × 10(6) ). Adverse events of plerixafor were mild to moderate and consisted of gastrointestinal side effects and local reactions at the injection site. Thirteen (48%) patients underwent autologous transplantation receiving a median of 2.93 × 10(6) CD34+ cells/kg (range, 1.46 × 10(6) -5.6 × 10(6) ) and showed a trilinear engraftment with a median neutrophil recovery on Day 12 and a platelet recovery on Day 14. Our study confirms previous investigations showing that plerixafor in combination with G-CSF is an effective and well-tolerated mobilization regimen with the potential of successful stem cell collection in patients with previous mobilization failure. © 2010 American Association of Blood Banks.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Adult -
Aged -
Antigens, CD34 - metabolism
Antigens, CD34 -
Combined Modality Therapy -
Drug Therapy, Combination -
Female -
Granulocyte Colony-Stimulating Factor - administration & dosage
Hematopoietic Stem Cell Mobilization - methods
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic Stem Cells - cytology Hematopoietic Stem Cells - metabolism
Heterocyclic Compounds - administration & dosage
Humans -
Immunoglobulin G - therapeutic use
Leukapheresis -
Lymphoma - drug therapy
Male -
Melphalan - therapeutic use
Middle Aged -
Multiple Myeloma - drug therapy
Receptors, CXCR4 - antagonists & inhibitors
Transplantation, Autologous -
Young Adult -

© Meduni Graz Impressum